Inhibition of A/Human/Hubei/3/2005 (H3N2) influenza virus infection by silver nanoparticles in vitro and in vivo

Dongxi Xiang,1 Yang Zheng,2 Wei Duan,1 Xiujing Li,3 Jianjian Yin,3 Sarah Shigdar,1 Michael Liam O’Connor,1 Manju Marappan,1 Xiaojuan Zhao,4 Yingqiu Miao,3 Bin Xiang,5 Conglong Zheng31School of Medicine, Deakin University, Waurn Ponds, Victoria, Australia; 2Department of Pharmacology, Osaka...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Xiang DX, Zheng Y, Duan W, Li XJ, Yin JJ, Shigdar S, O&#39;Connor ML, Marappan M, Zhao XJ, Miao YQ, Xiang B, Zheng CL
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/686f1f38c41940e68ec455cfbe117cf1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:686f1f38c41940e68ec455cfbe117cf1
record_format	dspace
spelling	oai:doaj.org-article:686f1f38c41940e68ec455cfbe117cf12021-12-02T02:43:00ZInhibition of A/Human/Hubei/3/2005 (H3N2) influenza virus infection by silver nanoparticles in vitro and in vivo1176-91141178-2013https://doaj.org/article/686f1f38c41940e68ec455cfbe117cf12013-10-01T00:00:00Zhttp://www.dovepress.com/inhibition-of-ahumanhubei32005-h3n2-influenza-virus-infection-by-silve-a14822https://doaj.org/toc/1176-9114https://doaj.org/toc/1178-2013Dongxi Xiang,1 Yang Zheng,2 Wei Duan,1 Xiujing Li,3 Jianjian Yin,3 Sarah Shigdar,1 Michael Liam O’Connor,1 Manju Marappan,1 Xiaojuan Zhao,4 Yingqiu Miao,3 Bin Xiang,5 Conglong Zheng31School of Medicine, Deakin University, Waurn Ponds, Victoria, Australia; 2Department of Pharmacology, Osaka University, Osaka, Japan; 3Department of Biology, Medical College, Dalian University, Liaoning, People’s Republic of China; 4Department of Gynaecology and Obstetrics, Qingdao Central Hospital, Shandong, People’s Republic of China; 5Department of Oral Medicine and Medical Research Center, Medical College, Dalian University, Liaoning, People’s Republic of ChinaAbstract: Silver nanoparticles (AgNPs) have attracted much attention as antimicrobial agents and have demonstrated efficient inhibitory activity against various viruses, including human immunodeficiency virus, hepatitis B virus, and Tacaribe virus. In this study, we investigated if AgNPs could have antiviral and preventive effects in A/Human/Hubei/3/2005 (H3N2) influenza virus infection. Madin-Darby canine kidney cells infected with AgNP-treated H3N2 influenza virus showed better viability (P<0.05 versus influenza virus control) and no obvious cytopathic effects compared with an influenza virus control group and a group treated with the solvent used for preparation of the AgNPs. Hemagglutination assay indicated that AgNPs could significantly inhibit growth of the influenza virus in Madin-Darby canine kidney cells (P<0.01 versus the influenza virus control). AgNPs significantly reduced cell apoptosis induced by H3N2 influenza virus at three different treatment pathways (P<0.05 versus influenza virus control). H3N2 influenza viruses treated with AgNPs were analyzed by transmission electron microscopy and found to interact with each other, resulting in destruction of morphologic viral structures in a time-dependent manner in a time range of 30 minutes to 2 hours. In addition, intranasal AgNP administration in mice significantly enhanced survival after infection with the H3N2 influenza virus. Mice treated with AgNPs showed lower lung viral titer levels and minor pathologic lesions in lung tissue, and had a marked survival benefit during secondary intranasal passage in vivo. These results provide evidence that AgNPs have beneficial effects in preventing H3N2 influenza virus infection both in vitro and in vivo, and demonstrate that AgNPs can be used as potential therapeutics for inhibiting outbreaks of influenza.Keywords: silver nanoparticles, influenza virus, H3N2, antiviral activityXiang DXZheng YDuan WLi XJYin JJShigdar SO&#39;Connor MLMarappan MZhao XJMiao YQXiang BZheng CLDove Medical PressarticleMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2013, Iss Issue 1, Pp 4103-4114 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Xiang DX Zheng Y Duan W Li XJ Yin JJ Shigdar S O&#39;Connor ML Marappan M Zhao XJ Miao YQ Xiang B Zheng CL Inhibition of A/Human/Hubei/3/2005 (H3N2) influenza virus infection by silver nanoparticles in vitro and in vivo
description	Dongxi Xiang,1 Yang Zheng,2 Wei Duan,1 Xiujing Li,3 Jianjian Yin,3 Sarah Shigdar,1 Michael Liam O’Connor,1 Manju Marappan,1 Xiaojuan Zhao,4 Yingqiu Miao,3 Bin Xiang,5 Conglong Zheng31School of Medicine, Deakin University, Waurn Ponds, Victoria, Australia; 2Department of Pharmacology, Osaka University, Osaka, Japan; 3Department of Biology, Medical College, Dalian University, Liaoning, People’s Republic of China; 4Department of Gynaecology and Obstetrics, Qingdao Central Hospital, Shandong, People’s Republic of China; 5Department of Oral Medicine and Medical Research Center, Medical College, Dalian University, Liaoning, People’s Republic of ChinaAbstract: Silver nanoparticles (AgNPs) have attracted much attention as antimicrobial agents and have demonstrated efficient inhibitory activity against various viruses, including human immunodeficiency virus, hepatitis B virus, and Tacaribe virus. In this study, we investigated if AgNPs could have antiviral and preventive effects in A/Human/Hubei/3/2005 (H3N2) influenza virus infection. Madin-Darby canine kidney cells infected with AgNP-treated H3N2 influenza virus showed better viability (P<0.05 versus influenza virus control) and no obvious cytopathic effects compared with an influenza virus control group and a group treated with the solvent used for preparation of the AgNPs. Hemagglutination assay indicated that AgNPs could significantly inhibit growth of the influenza virus in Madin-Darby canine kidney cells (P<0.01 versus the influenza virus control). AgNPs significantly reduced cell apoptosis induced by H3N2 influenza virus at three different treatment pathways (P<0.05 versus influenza virus control). H3N2 influenza viruses treated with AgNPs were analyzed by transmission electron microscopy and found to interact with each other, resulting in destruction of morphologic viral structures in a time-dependent manner in a time range of 30 minutes to 2 hours. In addition, intranasal AgNP administration in mice significantly enhanced survival after infection with the H3N2 influenza virus. Mice treated with AgNPs showed lower lung viral titer levels and minor pathologic lesions in lung tissue, and had a marked survival benefit during secondary intranasal passage in vivo. These results provide evidence that AgNPs have beneficial effects in preventing H3N2 influenza virus infection both in vitro and in vivo, and demonstrate that AgNPs can be used as potential therapeutics for inhibiting outbreaks of influenza.Keywords: silver nanoparticles, influenza virus, H3N2, antiviral activity
format	article
author	Xiang DX Zheng Y Duan W Li XJ Yin JJ Shigdar S O&#39;Connor ML Marappan M Zhao XJ Miao YQ Xiang B Zheng CL
author_facet	Xiang DX Zheng Y Duan W Li XJ Yin JJ Shigdar S O&#39;Connor ML Marappan M Zhao XJ Miao YQ Xiang B Zheng CL
author_sort	Xiang DX
title	Inhibition of A/Human/Hubei/3/2005 (H3N2) influenza virus infection by silver nanoparticles in vitro and in vivo
title_short	Inhibition of A/Human/Hubei/3/2005 (H3N2) influenza virus infection by silver nanoparticles in vitro and in vivo
title_full	Inhibition of A/Human/Hubei/3/2005 (H3N2) influenza virus infection by silver nanoparticles in vitro and in vivo
title_fullStr	Inhibition of A/Human/Hubei/3/2005 (H3N2) influenza virus infection by silver nanoparticles in vitro and in vivo
title_full_unstemmed	Inhibition of A/Human/Hubei/3/2005 (H3N2) influenza virus infection by silver nanoparticles in vitro and in vivo
title_sort	inhibition of a/human/hubei/3/2005 (h3n2) influenza virus infection by silver nanoparticles in vitro and in vivo
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/686f1f38c41940e68ec455cfbe117cf1
work_keys_str_mv	AT xiangdx inhibitionofahumanhubei32005h3n2influenzavirusinfectionbysilvernanoparticlesinvitroandinvivo AT zhengy inhibitionofahumanhubei32005h3n2influenzavirusinfectionbysilvernanoparticlesinvitroandinvivo AT duanw inhibitionofahumanhubei32005h3n2influenzavirusinfectionbysilvernanoparticlesinvitroandinvivo AT lixj inhibitionofahumanhubei32005h3n2influenzavirusinfectionbysilvernanoparticlesinvitroandinvivo AT yinjj inhibitionofahumanhubei32005h3n2influenzavirusinfectionbysilvernanoparticlesinvitroandinvivo AT shigdars inhibitionofahumanhubei32005h3n2influenzavirusinfectionbysilvernanoparticlesinvitroandinvivo AT oamp39connorml inhibitionofahumanhubei32005h3n2influenzavirusinfectionbysilvernanoparticlesinvitroandinvivo AT marappanm inhibitionofahumanhubei32005h3n2influenzavirusinfectionbysilvernanoparticlesinvitroandinvivo AT zhaoxj inhibitionofahumanhubei32005h3n2influenzavirusinfectionbysilvernanoparticlesinvitroandinvivo AT miaoyq inhibitionofahumanhubei32005h3n2influenzavirusinfectionbysilvernanoparticlesinvitroandinvivo AT xiangb inhibitionofahumanhubei32005h3n2influenzavirusinfectionbysilvernanoparticlesinvitroandinvivo AT zhengcl inhibitionofahumanhubei32005h3n2influenzavirusinfectionbysilvernanoparticlesinvitroandinvivo
_version_	1718402223725084672

Inhibition of A/Human/Hubei/3/2005 (H3N2) influenza virus infection by silver nanoparticles in vitro and in vivo

Ejemplares similares